Navigation Links
Mobility-enhancing device developed at University of Alberta will receive prestigious da Vinci Award
Date:9/25/2007

September 25, 2007 Edmonton, Alberta Over a decade in the making, the WalkAide System is a small device that makes a big difference for its users. Now the Canadian invention is receiving international recognition as a recipient of a 2007 da Vinci Award, to be presented by General Motors at the Ritz-Carlton Hotel, Dearborn, MI, on Friday, September 28, 2007.

Created at the University of Alberta in Edmonton, Canada, by a team led by Richard Stein, the WalkAide System is designed to assist users with foot drop, due to stroke, spinal cord injury, MS or cerebral palsy. The AA battery-operated device is about the size of an IPod and is worn around the leg, just below the knee.

WalkAide uses light electrical stimulation to re-train the muscles of the leg and ankle to move properly. The way the WalkAide works is that it has built-in electronic stimulation which activates some surface electrodes on the skin, so it doesn't need any implantation or surgery, said Stein, a professor emeritus in the U of As department of physiology in the Faculty of Medicine.

The timing of the stimulation is determined by a tilt censor. So when the leg tilts back, it turns the stimulus on, and when the leg tilts forward, it turns it off.

In the spirit of the 15th century artist and visionary Leonardo da Vinci, the da Vinci Awards honour the most innovative developments and research in adaptive and assistive technology that embrace the Universal Design Principlean approach to the design of products, services and environments to be usable by as many people as possible regardless of age, ability or circumstance.

For users of the WalkAide, the device means mobility, independence and a renewed sense of freedom. It is truly life changing, said Edgar Jackson of Edmonton, Canada, who has foot drop as a result of a motorcycle accident and has used WalkAide for six years. I owe this man everything, Jackson said in reference to Stein.


'/>"/>

Contact: Isabela Varela
isabela.varela@ualberta.ca
780-492-6041
University of Alberta
Source:Eurekalert

Page: 1

Related medicine news :

1. Alerts for safety of heart device
2. New device to help spinal cord injury cases walk
3. FDA approves new device to treat womens bleeding disorder
4. A new hearing device improves hearing
5. New device for detecting artery blockages
6. New device for discerning Osteoarthritis
7. Screening device for ovarian cancer
8. Innovative device aids in advanced heart failure
9. Vacuum device increase breasts
10. Latest device for identifying Melanomas
11. Injection supports Heart Devices
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10BioCryst Provides Update Regarding Peramivir for Influenza 5116 1BioCryst Provides Update Regarding Peramivir for Influenza 5116 2BioCryst Provides Update Regarding Peramivir for Influenza 5116 3BioCryst Provides Update Regarding Peramivir for Influenza 5116 4BioCryst Provides Update Regarding Peramivir for Influenza 5116 5Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3Doctor Visits Are Getting Short Shrift in Tight Economy 58589 1Doctor Visits Are Getting Short Shrift in Tight Economy 58589 2